Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient
Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study. The snapshot looks at twelve of the key indices captured in Therapy Watch data.
What next for the treatment of Psoriasis in Europe?
Research Director Laurent Chanroux investigates the changing market dynamics in Psoriasis in Europe.
Over the last decade, systemic biologic therapies for Psoriasis (PsO) have become widespread and the development of biological therapies has revolutionized the treatment of the disease. A chronic autoimmune disease, psoriasis has an estimated prevalence of 2.5% in Europe, representing approximately 15 million people, with 20–25% of these suffering from severe disease.
Are biosimilars the answer to the rising cost of RA treatment?
Our latest Free Thinking white paper explores why the uptake of Biosimilars has been slower than expected and asks what's next for RA?
Monoclonal-antibody (mAb) biologics have significantly improved treatment options and outcomes in rheumatoid arthritis (RA), particularly where patients do not respond to conventional disease-modifying anti-rheumatics.
The burden of disease from RA, including the cost of treatment, additional care and loss of productivity, is considerable. With disease onset peaking at 55 to 64 years, this burden will increase as populations age worldwide, aggravated by rising obesity and other characteristics of unhealthy lifestyles. Therapeutic mAbs, are helping to ease that load. As with most biologics, however, they come at a substantial cost.
In a past Free Thinking paper, we looked at the opportunity and challenges for biosimilar mAbs entering the rheumatoid arthritis market. A few years later and according to our Therapy Watch patient record data, uptake of biosimilars remains relatively muted, with marked inconsistencies across the major European markets. With Enbrel biosimilar Benepali about to launch across EU, we ask what’s next for RA?
AAD Conference 2016
Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients
We were delighted to present a poster at the 74th annual meeting of the American Academy of Dermatology, earlier this month. The poster, which is entitled: ‘A real world review of treatment duration and persistence among European psoriasis patients’ is authored by Research Director, Laurent Chanroux and Research Executive, Lauren Royel.
Biosimilars: Friend or Foe?
Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.